Preinterventional pan-immune-inflammation value as a tool to predict postcontrast acute kidney injury among acute coronary syndrome patients implanted drug-eluting stents: a retrospective observational study.

IF 1.3 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Scandinavian Journal of Clinical & Laboratory Investigation Pub Date : 2024-04-01 Epub Date: 2024-03-20 DOI:10.1080/00365513.2024.2330904
Alparslan Kurtul, Murat Gok
{"title":"Preinterventional pan-immune-inflammation value as a tool to predict postcontrast acute kidney injury among acute coronary syndrome patients implanted drug-eluting stents: a retrospective observational study.","authors":"Alparslan Kurtul, Murat Gok","doi":"10.1080/00365513.2024.2330904","DOIUrl":null,"url":null,"abstract":"<p><p>We evaluated the value of pan-immune-inflammation value (PIV) in predicting the risk for postcontrast acute kidney injury (PCAKI), an important complication following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients. Medical records of 839 ACS patients underwent PCI between June 2019 and December 2022 were retrospectively analyzed. Patients were divided into two groups: PCAKI (-) and PCAKI (+). PCAKI was defined as <i>a</i> ≥ 0.5 mg/dL and/or <i>a</i> ≥ 25% increase in serum creatinine within 72 h after PCI. The PIV was computed as [neutrophils × platelets × monocytes]÷lymphocytes. The mean age was 60.7 ± 12.9 years. PCAKI was detected in 105 (12.51%) patients. PIV was higher in the PCAKI (+) group compared to PCAKI (-) group (median 1150, interquartile range [IQR] 663-2021 vs median 366, IQR 238-527, <i>p</i> < 0.001). Receiver operating characteristic curve analysis showed that the best cutoff of PIV for predicting PCAKI was 576 with 81% sensitivity and 80% specificity. PIV was superior to neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for the prediction of PCAKI (area under curve:0.894, 0.849 and 0.817, respectively, <i>p</i> < 0.001 for all). A high PIV was independently correlated with PCAKI (≤576 vs. >576, odds ratio [OR] 12.484, 95%confidence interval [CI] 4.853-32.118, <i>p</i> < 0.001) together with older age (OR 1.058, <i>p</i> = 0.009), female gender (OR 4.374, <i>p</i> = 0.005), active smoking (OR 0.193, <i>p</i> = 0.012), left ventricular ejection fraction (OR 0.954, <i>p</i> = 0.021), creatinine (OR 10.120, <i>p</i> < 0.001), hemoglobin (OR 0.759, <i>p</i> = 0.019) and c-reactive protein (OR 1.121, <i>p</i> = 0.002). In conclusion, a high PIV seems to be an easily assessable tool that can be used in clinical practice for predicting the risk of PCAKI in ACS patients implanted drug-eluting stents.</p>","PeriodicalId":21474,"journal":{"name":"Scandinavian Journal of Clinical & Laboratory Investigation","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Clinical & Laboratory Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00365513.2024.2330904","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

We evaluated the value of pan-immune-inflammation value (PIV) in predicting the risk for postcontrast acute kidney injury (PCAKI), an important complication following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients. Medical records of 839 ACS patients underwent PCI between June 2019 and December 2022 were retrospectively analyzed. Patients were divided into two groups: PCAKI (-) and PCAKI (+). PCAKI was defined as a ≥ 0.5 mg/dL and/or a ≥ 25% increase in serum creatinine within 72 h after PCI. The PIV was computed as [neutrophils × platelets × monocytes]÷lymphocytes. The mean age was 60.7 ± 12.9 years. PCAKI was detected in 105 (12.51%) patients. PIV was higher in the PCAKI (+) group compared to PCAKI (-) group (median 1150, interquartile range [IQR] 663-2021 vs median 366, IQR 238-527, p < 0.001). Receiver operating characteristic curve analysis showed that the best cutoff of PIV for predicting PCAKI was 576 with 81% sensitivity and 80% specificity. PIV was superior to neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for the prediction of PCAKI (area under curve:0.894, 0.849 and 0.817, respectively, p < 0.001 for all). A high PIV was independently correlated with PCAKI (≤576 vs. >576, odds ratio [OR] 12.484, 95%confidence interval [CI] 4.853-32.118, p < 0.001) together with older age (OR 1.058, p = 0.009), female gender (OR 4.374, p = 0.005), active smoking (OR 0.193, p = 0.012), left ventricular ejection fraction (OR 0.954, p = 0.021), creatinine (OR 10.120, p < 0.001), hemoglobin (OR 0.759, p = 0.019) and c-reactive protein (OR 1.121, p = 0.002). In conclusion, a high PIV seems to be an easily assessable tool that can be used in clinical practice for predicting the risk of PCAKI in ACS patients implanted drug-eluting stents.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
将介入前泛免疫炎症值作为预测植入药物洗脱支架的急性冠脉综合征患者造影后急性肾损伤的工具:一项回顾性观察研究。
我们评估了泛免疫炎症值(PIV)在预测急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)后的重要并发症--造影后急性肾损伤(PCAKI)风险方面的价值。研究人员对2019年6月至2022年12月期间接受PCI治疗的839名ACS患者的病历进行了回顾性分析。患者被分为两组:PCAKI(-)组和PCAKI(+)组。PCAKI定义为PCI术后72小时内血清肌酐升高≥0.5 mg/dL和/或≥25%。PIV计算公式为[中性粒细胞×血小板×单核细胞]÷淋巴细胞。平均年龄为 60.7 ± 12.9 岁。105例(12.51%)患者检测到PCAKI。与 PCAKI (-) 组相比,PAKI (+) 组的 PIV 更高(中位数 1150,四分位数间距 [IQR] 663-2021 vs 中位数 366,IQR 238-527,p p 576,几率比 [OR] 12.484,95% 置信区间 [CI]4.853-32.118,p p = 0.009)、女性性别(OR 4.374,P = 0.005)、主动吸烟(OR 0.193,P = 0.012)、左室射血分数(OR 0.954,P = 0.021)、肌酐(OR 10.120,P = 0.019)和 c 反应蛋白(OR 1.121,P = 0.002)。总之,高 PIV 似乎是一种易于评估的工具,可在临床实践中用于预测植入药物洗脱支架的 ACS 患者发生 PCAKI 的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.50
自引率
4.80%
发文量
85
审稿时长
4-8 weeks
期刊介绍: The Scandinavian Journal of Clinical and Laboratory Investigation is an international scientific journal covering clinically oriented biochemical and physiological research. Since the launch of the journal in 1949, it has been a forum for international laboratory medicine, closely related to, and edited by, The Scandinavian Society for Clinical Chemistry. The journal contains peer-reviewed articles, editorials, invited reviews, and short technical notes, as well as several supplements each year. Supplements consist of monographs, and symposium and congress reports covering subjects within clinical chemistry and clinical physiology.
期刊最新文献
Significance of myeloperoxidase, pentraxin-3 and soluble urokinase plasminogen activator receptor determination in patients with moderate carotid artery stenosis. Reliability of albumin bromocresol green colorimetric method and clinical impact. Hb Tacoma by seven HbA1c methods - one with significant interference. A retrospective study on biotinidase deficiency: analysis of the Eastern Anatolia region patient cohort. The eGFRcystatin C/eGFRcreatinine-ratio is associated with maternal morbidity in hypertensive disorders in pregnancy and may indicate optimal timing of delivery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1